63001-30-9

Usage

Uses

Used in Organic Synthesis:
Methyl 6-oxo-1,6-dihydropyridazine-3-carboxylate is utilized as a key intermediate in organic synthesis for the preparation of various chemical compounds. Its versatile structure allows for the synthesis of a wide range of molecules with potential applications in different industries.
Used in Pharmaceutical Research:
In the pharmaceutical industry, Methyl 6-oxo-1,6-dihydropyridazine-3-carboxylate is employed as a starting material or building block in the development of new drugs and bioactive molecules. Its unique chemical properties and potential biological activities make it a valuable asset in the design and synthesis of innovative therapeutic agents.
Used in Drug Discovery:
Methyl 6-oxo-1,6-dihydropyridazine-3-carboxylate is used as a potential lead compound in drug discovery. Its biological activities and interactions with biological targets may provide insights into the development of new therapeutic agents with improved efficacy and selectivity.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, Methyl 6-oxo-1,6-dihydropyridazine-3-carboxylate is used for the exploration of its potential as a therapeutic agent. Its unique structure and properties may offer new opportunities for the design of novel drugs with specific pharmacological effects.
Overall, Methyl 6-oxo-1,6-dihydropyridazine-3-carboxylate is a versatile chemical compound with a wide range of applications in various industries, particularly in the development of new drugs and bioactive molecules. Its potential biological activities and unique structure make it an exciting area of research for chemists and pharmaceutical scientists.

InChI:InChI=1/C6H6N2O3/c1-11-6(10)4-2-3-5(9)8-7-4/h2-3H,1H3,(H,8,9)

Upstream product

• 67-56-1 methanol 
• 37972-69-3 6-oxo-1,6-dihydropyridazine-3-carboxylic acid 
• 37972-69-3 6-hydroxy-pyridazine-3-carboxylic acid 
• 27372-38-9 3-Hydroxy-6-carboxy-4.5-dihydro-pyridazin 
• 328-50-7 α-ketoglutaric acid 
• 56434-28-7 6-methoxypyridazine-3-carboxylic acid 
• 27372-38-9 6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylic acid 
• 19194-96-8 methyl 6-methoxypyridazine-3-carboxylate 
• 89532-94-5 methyl 6-oxo-1,4,5,6-tetrahydropyridazine-3-carboxylate 

Downstream Products

• 103854-71-3 1-butyl-6-oxo-1,6-dihydro-pyridazine-3-carboxylic acid 
• 65202-50-8 methyl 6-chloro-3-pyridazinecarboxylate 
• 98140-96-6 6-aminopyridazine-3-carboxylic acid methyl ester 
• 98021-39-7 6-oxy-1,6-dihydropyridazine-3-carboxylic acid hydrazine 
• 840488-99-5 6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridazine-3-carboxylic acid methyl ester 
• 840488-98-4 6-(4-(2-(trifluoromethyl)benzoyl)piperazin-1-yl)pyridazine-3-carboxylic acid 
• 840491-71-6 6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridazine-3-carboxylic acid (4-chlorophenyl)amide 
• 840491-76-1 6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridazine-3-carboxylic acid pyridin-2-ylamide 
• 840491-78-3 6-[4-(2-trifluoromethylbenzoyl)-piperazin-1-yl]pyridazine-3-carbonyl chloride 
• 840491-81-8 6-[4-(2-trifluoromethylbenzoyl)piperazin-1-yl]pyridazine-3-carboxylic acid (pyridin-2-yl-methyl)amide 

Relevant academic research and scientific papers

METHODS OF MANUFACTURING A BIFUNCTIONAL COMPOUND, ULTRAPURE FORMS OF THE BIFUNCTIONAL COMPOUND, AND DOSAGE FORMS COMPRISING THE SAME

The present disclosure relates to ultra-pure forms, polymorphs, amorphous forms, and formulations of N-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]-6-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl}methyl)piperidin-1-yl]pyridazine-3-carboxamide, referred to herein as Compound A: The present disclosure also relates methods of manufacturing and purifying the same, as well as intermediates useful in the synthesis of Compound A. The ultra-pure forms, polymorphs, amorphous forms, and formulations of Compound A can be used as therapeutic agents for the treatment of various diseases and conditions such as cancer.

PYRIDAZINONE COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISEASES

Substituted pyridazinone compounds, conjugates, and pharmaceutical compositions for use in the treatment of neuromuscular diseases, such as Duchenne Muscular Dystrophy (DMD), are disclosed herein. The disclosed compounds are useful, among other things, in the treating of DMD and modulating inflammatory inhibitors IL-1, IL-6 or TNF-α.

Development of a Scalable Synthesis of the Small Molecule TGFβR1 Inhibitor BMS-986260

A scalable route to the small molecule TGFβR1 inhibitor BMS-986260 (1) was developed. This alternative approach circumvented the purification of intermediates by column chromatography and provided access to multikilogram quantities of the key intermediate

VINYL COMPOUNDS AS FGFR AND VEGFR INHIBITORS

FGFR and VEGFR inhibitors are provided, and compounds represented by formula (1) or formula (II) as FGFR and VEGFR inhibitors, pharmaceutically acceptable salts or tautomers thereof are specifically disclosed.

Piperazine derivatives and their use as therapeutic agents

Compounds for treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the compounds are of formula (I): where x y, W, V, R 2 , R 3 , R 4 , R 5 , R 6 , R 6a , R 7 , R 7a , R 8 , R 8a , R 9 and R 9a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.

TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF

The present invention relates to compounds of Formula I and pharmaceutically acceptable compositions thereof, useful as TBK/IKKε inhibitors.

NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS

Compounds of Formula I: are HIV reverse transcriptase inhibitors, wherein R1, R2, RE, L, M and Z are defined herein. The compounds of Formula I and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines

5-PHENOXY-3H-PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS HIV REVERSE TRANSCRIPTASE INHIBITORS

Compounds of Formula (I) are HIV reverse transcriptase inhibitors, wherein R1, R2, RE, L, M and Z are defined herein. The compounds of Formula (I) and their pharmaceutically acceptable salts are useful in the inhibition of HIV reverse transcriptase, the prophylaxis and treatment of infection by HIV and in the prophylaxis, delay in the onset or progression, and treatment of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

3 (3-Pyrimidin-2-ylbenzyl)-1,2,4-triazolo[4,3-b]pyridazine derivatives

Compounds of the formula (I), in which R1, R2, R3, R3′, R4 have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for th

INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS

Disclosed are compounds of Formula (I): which are useful as antagonists of the CRTH2 receptors. Pharmaceutical compositions containing compounds of Formula (I) and the use of compounds of Formula (I) to treat diseases or disorders that are responsive to inhibition of the binding of endogenous ligands to the CRTH2 receptor are also disclosed. Methods for preparing and using these compounds are further described.